Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...

So much information surrounds weight-loss jabs and so understanding what to expect from them can feel daunting ...

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.